Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer
Information source: AHS Cancer Control Alberta
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Nausea; Neoplasms
Intervention: Olanzapine (Drug); Haldol (Drug)
Phase: Phase 3
Status: Terminated
Sponsored by: Alberta Health Services Official(s) and/or principal investigator(s):
Jose Pereira, Principal Investigator, Affiliation: Alberta Cancerboard
Summary
The purpose of this study is to compare the efficacy and safety of Haldol (haloperidol) and
olanzapine in the control of chronic nausea with advanced cancer patients who have failed
first line antiemetic therapy.
Clinical Details
Official title: A Randomized Double-blind, Parallel Group Study Comparing Olanzapine (Zyprexa) With Haloperidol (Novo-peridol) for the Relief of Nausea and Vomiting in Patients With Advanced Cancer
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: Severity of nausea on days 3 and 5
Detailed description:
The purpose of this study is to compare the efficacy and safety of haloperidol and
olanzapine in the control of chronic nausea with advanced cancer patients who have failed
first line antiemetic therapy.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- >18 years of age
- Significant nausea/vomiting
- Failed maxeran and domperidone
- Underlying treatment of causes has failed
- Adequate cognitive function
- Communicates well
Exclusion Criteria:
- Partial/complete bowel obstruction
- Currently taking Haldol or olanzapine
- Has drug induced extrapyramidal symptoms
- Parkinson's disease
- Undergoing chemotherapy or radiotherapy (RT) to brain, abdomen, stomach or esophagus
Locations and Contacts
Tom Baker Cancer Centre, Calgary, Alberta T2N 4N2, Canada
Additional Information
Starting date: May 2005
Last updated: January 18, 2012
|
